Clinical efficacy and pharmaceutical analysis of levofloxacin as adjuvant therapy for multidrug-resistant pulmonary tuberculosis
基于左氧氟沙星辅助治疗耐多药肺结核的临床效果并进行药学分析

摘要

目的 剖析耐多药肺结核用左氧氟沙星的作用。方法 2023年2月-2025年1月山东省新泰市中医医院接诊耐多药肺结核病人中随机选取72人，用电脑随机双盲法将72人均分成2组。试验组常规抗结核治疗期间加用左氧氟沙星，对照组行常规抗结核治疗。对比肺部空洞闭合时间等指标。结果 关于总有效率：试验组94.44%，对照组72.22%，P＜0.05。肺部空洞闭合时间、痰菌检查结核分歧杆菌转阴时间与肺部病灶吸收时间：试验组（71.51±7.28）d、（38.04±4.16）d、（65.94±6.03）d，对照组（93.27±9.13）d、（56.84±7.12）d、（91.59±19.12）d，差异显著（P＜0.05）。不良反应：8.33%，对照组13.89%，P＞0.05。sf-36评分：治疗后，试验组（88.94±3.02）分，对照组（82.17±4.54）分，差异显著（P＜0.05）。结论 耐多药肺结核病人常规抗结核治疗期间加用左氧氟沙星，其疗效、病情恢复及预后均得到显著改善，不良反应较少。

Abstract

Objective To analyze the effect of levofloxacin on multidrug-resistant pulmonary tuberculosis.
Methods From February 2023 to January 2025, 72 patients with multi drug resistant pulmonary tuberculosis were randomly selected from Xintai Hospital of Traditional Chinese Medicine in Shandong Province, and 72 patients were randomly divided into two groups by computer random double-blind method. The experimental group received routine anti tuberculosis treatment with levofloxacin, while the control group received routine anti tuberculosis treatment. Compare indicators such as the closure time of pulmonary cavities.
Results Regarding the total effective rate, the experimental group had a rate of 94.44%, while the control group had a rate of 72.22%, P＜0.05。 The closure time of pulmonary cavities, the time for tuberculosis bacilli to turn negative in sputum examination, and the time for lung lesion absorption were significantly different between the experimental group (71.51 ± 7.28) days, (38.04 ± 4.16) days, and (65.94 ± 6.03) days, and the control group (93.27 ± 9.13) days, (56.84 ± 7.12) days, and (91.59 ± 19.12) days (P<0.05). Adverse reactions: 8.33%, control group 13.89%, P＞0.05。 SF-36 score: After treatment, the experimental group scored (88.94 ± 3.02) points, while the control group scored (82.17 ± 4.54) points, with a significant difference (P<0.05).
Conclusion   Levofloxacin can significantly improve the efficacy, recovery and prognosis of multidrug resistant pulmonary tuberculosis patients during routine antituberculosis treatment, with less adverse reactions.